We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+37.79%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$2.62B
AUM Growth
+$630M
Cap. Flow
+$217M
Cap. Flow %
8.29%
Top 10 Hldgs %
54.13%
Holding
172
New
46
Increased
29
Reduced
19
Closed
33

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$64.1M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$36.1M
3
XLRN
Acceleron Pharma
XLRN
+$31.4M
4
PBYI icon
Puma Biotechnology
PBYI
+$17.7M
5
CBAY
Cymabay Therapeutics
CBAY
+$15.9M

Top Sells

Rank Stock Value
1
ARAV
Aravive, Inc. Common Stock
ARAV
+$42.4M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$36.7M
3
RDUS
Radius Health, Inc.
RDUS
+$29.2M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$20.9M
5
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.22%
2 Industrials 0.33%
3 Consumer Staples 0.16%
4 Consumer Discretionary 0.07%
5 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IVC
76
DELISTED
Invacare Corporation
IVC
$3.95M 0.15%
+200,000
New +$2.86M
GWPH
77
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$3.73M 0.14%
+36,763
New +$3.94M
NCNA
78
NuCana
NCNA
$6.12M
$3.67M 0.14%
+40
New +$3.45M
OCGN icon
79
Ocugen
OCGN
$475M
$3.52M 0.13%
29,630
– –
RGEN icon
80
Repligen
RGEN
$10.3B
$3.35M 0.13%
+87,400
New +$3.66M
GILD icon
81
Gilead Sciences
GILD
$184B
$3.24M 0.12%
+40,000
New +$3.06M
VRNA
82
DELISTED
Verona Pharma
VRNA
$3.07M 0.12%
200,000
– –
CRBP icon
83
Corbus Pharmaceuticals
CRBP
$219M
$2.96M 0.11%
13,823
-27,260
-66% -$5.33M
DBVT
84
PUT
DBV Technologies
DBVT
$941M
$2.81M 0.11%
+55,000
New +$23.6M
PFNX
85
DELISTED
Pfenex Inc.
PFNX
$2.56M 0.1%
845,973
– –
VIVE
86
DELISTED
VIVEVE MED INC
VIVE
$2.55M 0.1%
487
-403
-45% -$2.48M
OCRX
87
DELISTED
Ocera Therapeutics, Inc.
OCRX
$2.32M 0.09%
2,038,880
– –
ALNY icon
88
CALL
Alnylam Pharmaceuticals
ALNY
$32.1B
$2.31M 0.09%
+100,000
New +$8.54M
MGCD
89
DELISTED
MGC Diagnostics Corporation
MGCD
$2.26M 0.09%
252,327
– –
ADMA icon
90
ADMA Biologics
ADMA
$2.18B
$2.22M 0.08%
721,102
– –
MCRB icon
91
Seres Therapeutics
MCRB
$50.2M
$2.17M 0.08%
+6,750
New +$1.84M
ABEO icon
92
Abeona Therapeutics
ABEO
$355M
$1.99M 0.08%
4,676
-12,239
-72% -$3.29M
DCPH
93
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$1.95M 0.07%
+102,500
New +$1.88M
EIGR
94
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.73M 0.07%
5,256
– –
BCLI
95
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$1.65M 0.06%
26,667
– –
AFMD
96
DELISTED
Affimed
AFMD
$1.5M 0.06%
66,821
– –
CSBR icon
97
Champions Oncology
CSBR
$69.2M
$1.42M 0.05%
386,540
+19,567
+5% +$59.9K
CRIS icon
98
Curis
CRIS
$3.86M
$1.42M 0.05%
476
– –
ZYNE
99
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$1.32M 0.05%
+130,700
New +$1.38M
OSUR icon
100
OraSure Technologies
OSUR
$261M
$1.23M 0.05%
54,729
– –
2 3
4
5 6

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q3 2017 Portfolio in Review

As of Q3 2017, Perceptive Advisors held 172 positions worth $2.62B, up 32% from $1.99B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Perceptive Advisors deployed $217M of net new capital in Q3 2017, opening 46 new positions and adding to 29 existing holdings. Its largest new stake was Cymabay Therapeutics: 2,350,882 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Industrials and Consumer Staples.

On the sell side, the largest reduction was Aravive, Inc. Common Stock, an estimated $42.4M trimmed.

  • Perceptive Advisors's largest Q3 2017 buy was Cymabay Therapeutics: 2,350,882 shares worth $18.9M.
  • Perceptive Advisors added most to Neurocrine Biosciences in Q3 2017, an estimated $64.1M increase.
  • Perceptive Advisors's biggest Q3 2017 reduction was Aravive, Inc. Common Stock, cutting an estimated $42.4M.
  • Perceptive Advisors fully exited Sarepta Therapeutics in Q3 2017, selling an estimated $36.7M.
  • Perceptive Advisors's ten largest holdings make up 54% of its $2.62B portfolio in Q3 2017.
  • Perceptive Advisors opened 46 new positions and closed 33 in Q3 2017.
  • Perceptive Advisors's portfolio value rose 32% quarter-over-quarter to $2.62B.

Based on Perceptive Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.